PD 124966

02/01/1995 - "We investigated the in vivo selective anti-inflammatory effect of L-156,602, which was first identified as a preferential delayed-type hypersensitivity-suppressant in our screening program and first reported to be a C5a antagonist. "
10/01/1992 - "Preferential suppression of delayed-type hypersensitivity by L-156,602, a C5a receptor antagonist."
12/01/1992 - "L-156,602, a C5a receptor antagonist, was found as an immunosuppressant with preferential effects on delayed-type hypersensitivity (DTH) in our screening program and it was shown that L-156,602 suppressed the efferent phase of DTH. "

12/01/1992 - "These results demonstrated the unique immunomodulating properties of L-156,602 in mouse experimental models of inflammation."
02/01/1995 - "Although the dominant cell population that migrated in response to con A and zymosan 4 h after elicitation was neutrophils, L-156,602 specifically prevented the con-A-induced migration of neutrophils, suggesting a distinct mechanism of neutrophil recruitment between con A and zymosan-induced inflammation. "
12/01/1992 - "Muramyl dipeptide (MDP)-induced acute joint inflammation was also significantly suppressed by L-156,602. "
12/01/1992 - "The inflammation appeared 24 h after the elicitation with concanavalin A and it was significantly suppressed by L-156,602. "
12/01/1992 - "Effects of L-156,602, a C5a receptor antagonist, on mouse experimental models of inflammation."